第79届ADA-话题@MedSci

#第79届ADA#

3篇内容 | 276人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1803701, encodeId=99381803e01d1, content=<a href='/topic/show?id=ad51e57330e' target=_blank style='color:#2F92EE;'>#第79届ADA#</a>, objectTitle=第79届ADA：与GLP-1受体激动剂相比，Soliqua/Suliqua显著降低了2型糖尿病患者的血糖水平, objectType=article, longId=167983, objectId=85e516e98361, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=85e516e98361, replyNumber=0, likeNumber=48, createdTime=2020-05-02, rootId=0, userName=passed water, userId=a92e2500162, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=85e516e98361, moduleTitle=第79届ADA：与GLP-1受体激动剂相比，Soliqua/Suliqua显著降低了2型糖尿病患者的血糖水平, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=85e516e98361)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1803700, encodeId=f7ad1803e0032, content=<a href='/topic/show?id=ad51e57330e' target=_blank style='color:#2F92EE;'>#第79届ADA#</a>, objectTitle=第79届ADA：Dance 501吸入型胰岛素的II期临床结果喜人, objectType=article, longId=167971, objectId=033116e97107, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=033116e97107, replyNumber=0, likeNumber=43, createdTime=2019-07-03, rootId=0, userName=passed water, userId=a92e2500162, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=033116e97107, moduleTitle=第79届ADA：Dance 501吸入型胰岛素的II期临床结果喜人, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=033116e97107)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1803699, encodeId=fcf5180369981, content=<a href='/topic/show?id=ad51e57330e' target=_blank style='color:#2F92EE;'>#第79届ADA#</a>, objectTitle=第79届ADA：双重GIP和GLP-1受体激动剂tirzepatide治疗2型糖尿病的潜力, objectType=article, longId=167970, objectId=f88316e97041, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f88316e97041, replyNumber=0, likeNumber=55, createdTime=2019-06-22, rootId=0, userName=passed water, userId=a92e2500162, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f88316e97041, moduleTitle=第79届ADA：双重GIP和GLP-1受体激动剂tirzepatide治疗2型糖尿病的潜力, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f88316e97041)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

第79届ADA

2020-05-29

passed water (审核中...)

前往app查看评论内容

#第79届ADA#

第79届ADA：与GLP-1受体激动剂相比，Soliqua/Suliqua显著降低了2型糖尿病患者的血糖水平

2020-05-02

passed water (审核中...)

前往app查看评论内容

#第79届ADA#

第79届ADA：Dance 501吸入型胰岛素的II期临床结果喜人

2019-07-03

passed water (审核中...)

前往app查看评论内容

#第79届ADA#

第79届ADA：双重GIP和GLP-1受体激动剂tirzepatide治疗2型糖尿病的潜力

2019-06-22

科室
- - 订阅+
  - 更多科室
工具
服务